Concord Biotech Limited
Max Life Insurance marginally reduced its stake in Concord Biotech Limited from 1.34% to 1.33% by selling 8,826 shares.
An R&D-driven biopharma company engaged in manufacturing fermentation-based active pharmaceutical ingredients for immunosuppressants and oncology applications. Established in 1984, the company specializes in complex fermentation technology and serves domestic and international pharmaceutical markets with differentiated API solutions. Its focus on bioprocess innovation and vertical integration in fermentation-based manufacturing distinguishes it within the competitive global pharmaceutical ingredients landscape.
Now branded Axis Max Life after Axis Bank took a controlling stake. Crossed Rs 1.5 lakh crore in AUM in April 2024 with over 20% YoY growth and has continued to compound. CIO Sachin Bajaj has over 25 years of investment experience and runs a multi-cap equity book across ULIP, par and non-par funds with a quality and growth tilt.